https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2025-01-29 17:15:452025-01-29 17:17:07Charles Large, Autifony CEO, talks at the 8th Sachs Neuroscience Innovation Forum in San Francisco
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2024-07-22 09:58:402024-07-22 10:00:49Charles Large, Autifony CEO, talks to BiotechTV’s Amy Brown about progress in ion channel drug discovery and exciting hopes for novel treatments for rare paediatric epilepsy disorders.
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2024-03-27 11:31:412024-03-27 11:31:41Autifony Therapeutics announces publication in Nature Communications showing how novel Kv3 modulators with therapeutic potential can bind and enhance Kv3 ion channel function
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2023-11-14 07:08:292023-11-14 07:08:29Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2023-10-04 15:13:422023-10-04 15:15:48“Autifony provides an update to the National Fragile X Foundation on our research programme in Fragile X Syndrome”
https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svg00Wendy Kennedyhttps://autifony.com/wp-content/uploads/2022/05/autifony_therapeutics-Logo_RGB.svgWendy Kennedy2023-06-13 09:12:382023-06-13 09:12:38Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)